1.45
+0.02(+1.40%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.44 |
| Day High | 1.48 |
| Day Low | 1.36 |
| 52-Week High | 85.8 |
| 52-Week Low | 1.19 |
| Volume | 300,941 |
| Average Volume | 4.32M |
| Market Cap | 3.38M |
| PE | -0.05 |
| EPS | -29.01 |
| Moving Average 50 Days | 4.03 |
| Moving Average 200 Days | 8 |
| Change | 0.02 |
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
Positive human data and upcoming clinical catalysts across portfolioSOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modu
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
GlobeNewswire Inc.
Dec 23, 2025 2:00 PM GMT
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
GlobeNewswire Inc.
Dec 03, 2025 1:30 PM GMT
Findings further validate FABP5 inhibition and strengthen the therapeutic potential of Artelo’s FABP5 platform for mood and stress-related disordersSOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Ar